Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria: * histologically confirmed B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia arising from CLL/SLL or Richter's transformation according to WHO criteria who require therapy based on the 2008 revised IWCLL criteria. * Relapsed or refractory disease after receiving at least 1 prior therapy for CLL * At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater * Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than 2x IULN; serum creatinine less than 1.5x ULN) Exclusion Criteria: * have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to entering study * have not recovered from AEs due to agents administered more than 4 weeks prior * receiving any other investigational agent * known second malignancy that limits survival to less than 2 years * known HIV positive * uncontrolled intercurrent illness * pregnant or breastfeeding